Research Library › Neuropeptides
Cerebrolysin is not a single peptide but a standardized preparation of low-molecular-weight peptides and free amino acids made by controlled enzymatic breakdown of purified pig (porcine) brain protein. It is produced by the Austrian company EVER Neuro Pharma GmbH, formerly Ebewe Pharma, and is registered as a prescription medicine in a number of European and Asian countries. As of October 2026 it is not approved by the FDA and is not authorized for sale in the United States.
Key facts
| Type | Biological preparation: mixture of low-molecular-weight peptides (under 10 kDa) and free amino acids |
|---|---|
| Derived from | Enzymatic hydrolysate of purified porcine brain protein |
| Composition | About 15% peptides and 85% free amino acids by total nitrogen, per manufacturer patent; concentrate 215.2 mg/mL |
| First described | In use in Austria for decades; Ebewe Pharma production and use patent filed with 1990 priority |
| Developed by | Ebewe Pharma (now EVER Neuro Pharma GmbH), Unterach, Austria |
| Designed target | No single target; manufacturer proposes a multimodal, neurotrophic-like mode of action based on preclinical work |
| Regulatory status (Oct 2026) | Not FDA-approved or registered in the US; registered in a number of European and Asian countries |
Who developed it
Cerebrolysin was developed and is still made in Austria. The product was long associated with Ebewe Pharma, which filed a European patent on the preparation’s production and use with a 1990 priority date [1]. The company now operating as EVER Neuro Pharma GmbH, based in Unterach, Austria, holds the marketing authorization and bases its prescribing information on the Austrian summary of product characteristics [2].
Its research history spans several decades, with a large body of clinical and preclinical publications, many from Central and Eastern Europe, Russia and Asia [3].
Structure and composition
Unlike most compounds in this library, Cerebrolysin has no single amino acid sequence. It is made by standardized enzymatic hydrolysis of a purified protein fraction from pig brain. The process breaks the proteins into fragments, and the final solution is filtered so that the peptides it contains are under about 10,000 daltons in size [1, 4].
A 2026 EVER Neuro Pharma patent describes the preparation as roughly 15% low-molecular-weight peptides and about 85% free amino acids, measured by total nitrogen, with a standardized amino acid profile. It gives the concentrate strength as about 215.2 mg per mL [4]. The earlier Ebewe patent gave somewhat different proportions, a reminder that the composition is defined by the manufacturing process rather than by a fixed molecular formula [1].
Because it is a mixture, no single receptor target has been identified. The manufacturer describes a proposed multimodal mode of action drawn from laboratory and animal studies [4].
Research history
- 1990: Priority date of the Ebewe Pharma European patent on the peptide mixture [1]
- 1991: European patent application EP 0 452 299 published [1]
- 2010: First Cochrane review on the preparation in acute ischemic stroke published, later updated in 2020 and 2023 [3]
- 2017: EVER Neuro Pharma files a further use patent, granted in the US in March 2026 [4]
Clinical research has centered on research programs in acute ischemic stroke, traumatic brain injury and dementia. Independent systematic reviews, including Cochrane reviews, have assessed this literature [3]. This page does not summarize their findings.
Regulatory status as of October 2026
Cerebrolysin is not approved by the FDA. The manufacturer states that it is not registered with the FDA and is not approved for sale or distribution in the United States [2]. It is not listed in FDA’s May 2026 list of bulk drug substances nominated for 503A compounding [5].
Outside the US, Cerebrolysin is registered as a prescription injectable medicine in a number of European and Asian countries, where approvals include indications related to stroke [4]. A 2023 Cochrane review notes that it is widely used for acute ischemic stroke in Russia, Eastern Europe, China and other Asian and post-Soviet countries [3]. Approved indications vary by country [2].
About this reference page
Kalibra Labs does not currently supply Cerebrolysin. This page is published as a neutral scientific and regulatory reference. Browse the Neuropeptides guide or the FDA Peptide Regulatory Tracker.
Frequently asked questions
What is Cerebrolysin made from?
It is made by controlled enzymatic breakdown of purified protein from pig brain, producing a mixture of small peptides and free amino acids [1, 4].
Is Cerebrolysin a peptide?
It is a mixture rather than a single peptide. Most of its content by nitrogen is free amino acids, with a smaller fraction of peptides under about 10 kDa [4].
Who makes Cerebrolysin?
EVER Neuro Pharma GmbH of Unterach, Austria, formerly Ebewe Pharma, holds the marketing authorization [1, 2].
Is Cerebrolysin FDA approved?
No. As of October 2026 it is not FDA-approved, and the manufacturer states it is not registered with the FDA or approved for sale in the US [2].
Sources
- Ebewe Pharma GmbH Nfg KG (inventors Tsurusawa Y, Nishiyama M, Fujimoto M, Iwamoto N, Seki H). Method and composition for stimulating the growth of nerve processes. EP 0452299 A1; priority 12 Apr 1990, published 16 Oct 1991; B1 granted 18 Jun 1997. Link
- EVER Neuro Pharma GmbH. About Cerebrolysin (prescribing information based on the Austrian SmPC; US registration statement). Link
- Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2023;CD007026.pub7. Link
- Winter S, Mössler H (EVER Neuro Pharma GmbH). Method of prolonging the lifespan of patients with CADASIL using a Cerebrolysin preparation. US Patent 12,589,118 B2; priority 28 Aug 2017, granted 31 Mar 2026. Link
- U.S. FDA. Bulk drug substances nominated for use in compounding under section 503A, Categories 1–3 (updated 14 May 2026). Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
Kalibra Labs does not supply this compound. This page is a scientific, historical and regulatory reference only; it is not medical advice and makes no claim about use in people or animals.
